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Lymphomatosis cerebri:
a treatable cause of rapidly
progressive dementia
INTRODUCTION
Lymphomatosis cerebri (LC) is a rare
variant of primary central nervous system
lymphoma (PCNSL) pathologically char-
acterised by diffuse cerebral inﬁltration of
a non-cohesive mass of malignant lymph-
oid cells. We describe a case of rapidly
progressive dementia where MRI demon-
strated a diffuse leukoencephalopathy.
After a series of normal investigations,
brain biopsy was undertaken with hist-
ology consistent with LC. Our patient was
successfully treated with chemoradiother-
apy and neurorehabilitation. This case
underlines the importance of timely brain
biopsy in rapidly progressive cognitive
decline to allow earlier therapy for poten-
tially curable pathology.
CASE REPORT
A 50-year-old previously ﬁt and well lady
with no vascular risk factors presented to
her general practitioner with personality
change and emotional lability, against a
background of subacutely progressive
amnestic syndrome over 3 weeks. She
next developed severe anxiety and insom-
nia and was commenced on citalopram
and temazepam. Neurological examin-
ation demonstrated universally brisk
reﬂexes with no clonus and downgoing
plantar responses. There was marked lan-
guage difﬁculty with both expressive and
receptive components and ideational and
ideomotor apraxia. Formal neuropsycho-
metric testing showed marked impairment
in memory, naming, literacy skills and
information processing speed (all <5th
centile) with relative preservation of
executive functioning (phonemic ﬂuency
25th–50th centile). Testing was consistent
with marked and pervasive cognitive
dysfunction affecting mainly posterior,
cortical and subcortical regions.
Full blood count, C-reactive protein,
ESR, renal and liver function tests were
normal. EEG showed left temporal irregu-
lar slowing with occasional low-voltage
sharp waves suggestive of epileptiform
activity. MRI examination (ﬁgure 1A–C)
demonstrated extensive conﬂuent areas of
T2-weighted hyperintensity diffusely
throughout the cerebrum and brainstem.
There was no perceptible mass effect,
abnormal post-gadolinum contrast
enhancement nor restriction of diffusion of
the diffusion weighted imaging sequences.
The differential diagnoses included
infective pathology such as JC virus and
HIV, rapidly progressive inﬂammatory
demyelination and genetic metabolic
causes. The following were normal or
negative: JCV, HIV 1 and 2 and syphilis
serology; plasma amino acids, white cell
enzymes and very long chain fatty acids
levels. Copper studies, coeliac screen,
vitamin E levels, autoimmune antibody
tests, serum lactate, pyruvate, phytanic and
glutaric acid levels were also normal.
Cerebrospinal ﬂuid (CSF) examination
showed a protein level of 0.74 g/L with a
glucose of 3.2 mmol/L (serum 5.5
mmol/L), <1 white blood cell per millilitre
and negative oligoclonal bands. CSF PCR
for viruses including JC and HIV were also
negative. CSF cytology showed a moder-
ately cellular ﬂuid with increased numbers
of lymphocytes and macrophages with no
atypical cells, consistent with a mild
chronic inﬂammatory/reactive process.
Opthalmological screening revealed no
evidence of vitreoretinal disease.
Her cognitive symptoms deteriorated
over months to the point where she
required 24 h nursing care due to signiﬁ-
cant confusion and anxiety. She became too
unwell to engage in formal neuropsycho-
metric tests, but two senior neurologists
agreed that she had substantially deterio-
rated in posterior, cortical and subcortical
domains compared with the aforemen-
tioned neuropsychometry. A repeat MRI
(ﬁgure 1D–F) showed more extensive
signal changes in the frontal, parietal,
occipital and temporal lobes. This also
involved the right corticospinal tract, result-
ing in symmetrical T2-weighted hyperin-
tensity along the paired tracts through the
capsular, mesencephalic, pontine and
medullary regions. A further focus of T2-
weighted hyperintensity was seen in the left
cerebellar hemisphere. There was now
patchy enhancement in the peritrigonal
white matter bilaterally.
Given the rapid clinicoradiological pro-
gression and lack of diagnosis, a brain
biopsy of an enhancing region in the left
parietal lobe was performed. Histological
examination showed diffuse and nodular
inﬁltration of cerebrum by large atypical
lymphoid cells. The cells showed nuclear
pleomorphism and showed clusters around
blood vessels and diffuse spread into the
surrounding cortex. Further tests conﬁrmed
a diffuse large B cell lymphoma.
Following a bone marrow biopsy and
PET/CT scan, no evidence of lymphoma
outside the central nervous system was
found. Treatment commenced, including
high-dose methotrexate, cytarabine and
rituximab, followed by radiotherapy (40
Gy total). Repeat MRI showed signiﬁcant
improvement in the central nervous system
disease (ﬁgure 1G–I) and she also improved
functionally, being discharged home
without a package of care after previously
needing 24 h nursing care. Ten months
later, functional status had not deteriorated
and neuropsychometric testing was equiva-
lent to that done several months prior to
commencement of treatment (ie, before sig-
niﬁcant further cognitive decline), however
remaining below premorbid estimates.
Importantly, her gait and mobility also
improved dramatically as she went from
being unable to walk unaided immediately
prior to treatment, to walking independ-
ently, swimming twice weekly and using a
cross-trainer regularly.
DISCUSSION
PCNSL accounts for 3% of primary
central nervous system tumours.1 It typic-
ally presents as multifocal T2 hyperin-
tense lesions that both enhance after
gadolinium administration and demon-
strate mass effect. A case study in 1999
coined the term ‘lymphomatosis cerebri’
to describe an exceedingly rare variant of
PCNSL characterised by diffuse parenchy-
mal inﬁltration of lymphomatous cells.2
Previous presentations include gait dis-
turbance (mainly ataxic), personality
change, memory deﬁcits and weight loss.3
White matter abnormalities in LC have
been described affecting all regions of the
brain; however, serial MRI has rarely
been performed. We demonstrated rapid
progression of radiological features that tem-
porally correlated with clinical decline. We
also demonstrated transition from non-
enhancing to enhancing lesions perhaps sug-
gesting that progression and evolution of the
disease is associated with eventual disruption
of the blood–brain barrier.
Where LC was diagnosed premortem,
many cases responded to steroids alone, at
least initially.4 To achieve complete remis-
sion, steroid use has been followed by
radiotherapy, cisplatin or methotrexate.4
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There are many causes of rapidly pro-
gressive leukoencephalopathy including
inﬂammatory, vascular, immune, infec-
tious, neoplastic, drug and toxic causes,
neurodegenerative conditions and rarely
genetic leukoencephalopathy, for example,
cerebral adrenoleukodystrophy.
Nonetheless, rapid progression of struc-
tural change, perhaps combined with new
foci of enhancement, should prompt
thoughts of an underlying neoplastic
process and brain biopsy. A recent review
addressing the approach to diagnosing
adult onset leukodystrophy suggests the
diagnostic yield of biopsy is up to 78%
with management being altered in 63% of
cases.5 This case highlights the diagnostic
(and potential therapeutic) importance of
early consideration of brain biopsy in
patients with rapidly progressive atypical
neurological syndromes including cogni-
tive decline.
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Figure 1 Brain magnetic resonance imaging (MRI) at presentation (A–C), with coronal (A) and axial (B) T2-weighted sequences demonstrating
extensive white matter hyperintensity with no associated mass effect. Note the extension of the hyperintensity along the left corticospinal tract at
the level of the cerebral peduncle and pons (white arrow). Axial post-gadolinium contrast T1-weighted imaging (C) did not reveal any abnormal
enhancement at this stage. Brain MRI at 6 months after initial presentation (D–F) with coronal FLAIR (D) and axial T2-weighted (E) sequences
demonstrating progression and some mass effect of the white matter signal abnormality now involving both corticospinal tracts at the
mesencephalic and pontine levels (white arrows). The axial post-gadolinium contrast T1-weighted (F) imaging shows patchy peritrigonal white
matter enhancement. Follow-up MRI examination post-therapy (G–I) with coronal FLAIR (G) and axial T2-weighted (H) sequences demonstrating an
improvement in the extent and mass effect of the white matter hyperintensity and the resolution of peritrigonal white matter enhancement on the
axial post-gadolinium contrast T1-weighted (I) imaging.
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